Operating Income
Operating Income
Alnylam Pharmaceuticals Operating Income increased by 103.9% to $268.64M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1386.1%, from $18.08M to $268.64M. Over 4 years (FY 2021 to FY 2025), Operating Income shows an upward trend with a -8.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Income
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Growth in operating income suggests that the core business is becoming more profitable and efficient.
Detailed definition
The profit realized from a business's own operations after deducting operating expenses like wages, depreciation, and co...
Peer comparison
This is a key metric for comparing the fundamental business performance of companies with different tax or debt structures.
Metric ID:
operating_incomeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$146.16M | -$181.68M | -$194.56M | -$146.73M | -$191.69M | -$258.04M | -$188.61M | -$149.81M | -$229.83M | $213.87M | -$116.40M | -$43.44M | $48.61M | -$76.91M | -$105.16M | $18.08M | -$16.20M | $367.98M | $131.72M | $268.64M |
| QoQ Change | — | -24.3% | -7.1% | +24.6% | -30.6% | -34.6% | +26.9% | +20.6% | -53.4% | +193.1% | -154.4% | +62.7% | +211.9% | -258.2% | -36.7% | +117.2% | -189.6% | >999% | -64.2% | +103.9% |
| YoY Change | — | — | — | — | -31.1% | -42.0% | +3.1% | -2.1% | -19.9% | +182.9% | +38.3% | +71.0% | +121.2% | -136.0% | +9.7% | +141.6% | -133.3% | +578.5% | +225.3% | >999% |
Range-$258.04M – $367.98M
CAGR+13.7%
Avg YoY Growth+149.6%
Median YoY Growth+24.0%
Operating Income at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's operating income?
- Alnylam Pharmaceuticals (ALNY) reported operating income of $268.64M in Q1 2026.
- How has Alnylam Pharmaceuticals's operating income changed year-over-year?
- Alnylam Pharmaceuticals's operating income increased by 1386.1% year-over-year, from $18.08M to $268.64M.
- What is the long-term trend for Alnylam Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's operating income has grown at a -8.3% compound annual growth rate (CAGR), from -$708.65M to $501.58M.
- What does operating income mean?
- The profit earned from core business activities, before accounting for interest and taxes.